MorphoSys AG : Ad hoc: MorphoSys Signs Global License Agreement with GlaxoSmithKline for Anti-Inflammatory Program MOR103 and

     MorphoSys AG : Ad hoc: MorphoSys Signs Global License Agreement with
 GlaxoSmithKline for Anti-Inflammatory Program MOR103 and Increases Guidance

MorphoSys AG / License / Ad hoc: MorphoSys Signs Global License Agreement with
GlaxoSmithKline for Anti-Inflammatory Program MOR103 and Increases Guidance .
Processed and transmitted by Thomson Reuters ONE. The issuer is solely
responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that
they have entered into a global agreement with GlaxoSmithKline (GSK) to
develop and commercialize MOR103. MOR103 is MorphoSys's proprietary
HuCAL-derived antibody against GM-CSF, which has concluded Phase 1/2
development in mild to moderate rheumatoid arthritis.

Under the terms of the agreement, GSK will assume responsibility for all
subsequent development and commercialization of MOR103. As part of the
agreement, MorphoSys receives an immediate upfront payment of EUR 22.5
million. On achievement of certain developmental, regulatory, commercial and
sales-based milestones, MorphoSys would be eligible to receive additional
payments from GSK of up to EUR423 million, in addition to tiered,
double-digit royalties on net sales.

As a result of the transaction, MorphoSys increased its financial guidance for
2013. MorphoSys expects revenues of approximately EUR 68 million to EUR 72
million (previously EUR 48 million to EUR 52 million) and an EBIT of EUR -2
million to EUR +2 million (previously EUR -18 million to EUR -22 million). The
original guidance did not include a successful out-licensing of any of the
Company's proprietary development programs. Around EUR 20 million of the
upfront payment of EUR22.5 million shall be booked with signature. The
remaining amount shall be distributed over 2013 and 2014 according to the
development plan for the ongoing phase 1b MS trial of MOR103.


About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys
is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates about MorphoSys, visit

HuCAL^®, HuCAL GOLD^®, HuCAL PLATINUM^®, CysDisplay^®, RapMAT^®, arYla^® and
Ylanthia^® and 100 billion high potentials^® are registered trademarks of
MorphoSys AG.

Slonomics^® is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

Ad hoc announcement (PDF)


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE

--- End of Message ---

MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany

WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press spacebar to pause and continue. Press esc to stop.